Dr. Gilchuk received her PhD in molecular genetics in 2008 from the Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine (Kyiv, Ukraine). From 2008 to 2009, she held a staff scientist position in the Ukrainian Branch of Phage Biotechnology Corporation (Kyiv, Ukraine; San Diego, USA). During this time, her project employed recombinant phage antibody technology with the aim to design antibody fragments targeted against therapeutic proteins. The results of her work were covered by a declarative patent issued in Ukraine. From 2009 to 2012, she received postdoctoral training in Dr. Anthony Weil's laboratory at Vanderbilt University Medical Center, where she studied molecular mechanisms of transcriptional regulation. In 2012, Dr. Gilchuk continued her training by joining the Crowe Lab. Her project uses human B cell hybridoma technology to define the molecular genetic basis for the human neutralizing antibody response elicited by smallpox infection or vaccination.